Fortress Biotech Files 8-K on Financials
Ticker: FBIOP · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1429260
| Field | Detail |
|---|---|
| Company | Fortress Biotech, INC. (FBIOP) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k
Related Tickers: FBIO
TL;DR
FBIO dropped an 8-K detailing financial results - check it for the latest numbers.
AI Summary
Fortress Biotech, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. Fortress Biotech, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides investors with crucial updates on Fortress Biotech's financial health and operational performance, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- March 28, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1111 Kane Concourse (address) — Business Address
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on March 28, 2024.
What is the state of incorporation for Fortress Biotech, Inc.?
Fortress Biotech, Inc. is incorporated in Delaware.
What is the fiscal year end for Fortress Biotech, Inc.?
The fiscal year end for Fortress Biotech, Inc. is December 31.
What is the primary business address listed for Fortress Biotech, Inc.?
The primary business address is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-03-28 16:10:33
Filing Documents
- tm2410123d1_8k.htm (8-K) — 30KB
- tm2410123d1_ex99-1.htm (EX-99.1) — 101KB
- tm2410123d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-040521.txt ( ) — 365KB
- fbio-20240328.xsd (EX-101.SCH) — 4KB
- fbio-20240328_def.xml (EX-101.DEF) — 26KB
- fbio-20240328_lab.xml (EX-101.LAB) — 36KB
- fbio-20240328_pre.xml (EX-101.PRE) — 25KB
- tm2410123d1_8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 28, 2024, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the full year ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit Number Description 99.1 Press release issued by Fortress Biotech, Inc., dated March 28, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) By: /s/ Lindsay A. Rosenwald, M.D. Lindsay A. Rosenwald, M.D. Chairman, President and Chief Executive Officer Date: March 28, 2024